Risk Factors Update Summary

• Net income decreased from $872.1 million in 2022 to a net loss of $92.5 million in 2023.
• Uncertainty in obtaining/maintaining adequate coverage and reimbursement for products may limit revenue generation.
• Cash, cash equivalents, and marketable securities decreased from $327 million to $102.5 million.
• Potential future financing through equity issuance may impact research, development, and commercialization activities.
• Reimbursement policies may reduce demand for products, impacting commercialization success and profitability.
• Loss from continuing operations increased from $55.8 million to $909.1 million in 2023.
• Collaboration with Viatris terminated, impacting the development and commercialization of certain products.
• Third-party payors increasingly challenge prices, coverage, and cost-effectiveness, potentially limiting future product sales.
• Operating expenses are expected to increase in 2024 for sales and marketing expenditures.
• Changes in tax laws and regulations may affect earnings in countries with differing statutory tax rates.
• Capital return program of $325.3 million undertaken in September 2022, with $324.9 million repurchased by December 31, 2023.
• Being classified as a "smaller reporting company" may lead to reduced reporting and disclosure requirements.